Pyxis Oncology to acquire antibody therapeutics company Apexigen


Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share.

For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise value of approximately $16 million.

“This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanised antibody generation to our Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfizer, and expands our clinical pipeline into Phase II in select solid tumour types by leveraging our founding heritage of immuno-oncology expertise – all while maintaining our cash runway into 2025,” said Lara Sullivan, President and Chief Executive Officer of Pyxis Oncology.

Apexigen’s sotigalimab is a potential best-in-class Phase II CD40 agonist, that has demonstrated rapid, deep and durable responses across difficult-to-treat tumour types. It has been evaluated in more than 500 patients in clinical trials and demonstrated strong activity, including rapid, deep and durable responses and a favourable tolerability profile.

Xiaodong Yang, Chief Executive Officer of Apexigen, stated: “I am proud of the foundational work Apexigen has done to advance sotigalimab into Phase II trials across multiple solid tumour types. With Pyxis Oncology’s strong cash position and its commitment to further sotigalimab’s development, we believe that this transaction will greatly enhance the opportunity to efficiently advance sotigalimab for patients suffering from a variety of difficult-to-treat cancers.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free